Gene therapy development
Neurophth seeks to discover and develop gene therapies for patients with blindness and other eye diseases globally.
Source: LinkedIn company description · Retrieved October 13, 2026
Neurophth is a China-based gene therapy company focused on ophthalmic diseases.
Neurophth is headquartered in Wuhan, with subsidiaries in Shanghai, Suzhou, and the USA, and seeks to discover and develop gene therapies for blindness and other eye diseases globally. The company uses AAV and CMC platforms in work on gene therapies for LHON, autosomal dominant optic atrophy, vascular retinopathy, optic neuropathy, and other genetic diseases.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Neurophth seeks to discover and develop gene therapies for patients with blindness and other eye diseases globally.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Snapshot: September 18, 2026
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 15, 2026 and September 18, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.